AstraZeneca and Daiichi Sankyo’s ENHERTU (fam-trastuzumab deruxtecan-nxki), a specifically engineered HER2-directed antibody drug conjugate (ADC), has been approved by the U.S. FDA for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen and have developed disease recurrence during or within six months of completing therapy.   The approval was based on positive results from the DESTINY-Breast03 Phase III trial tha...